8-K filed May 5, 2026, 7:59 PM ET ticker AHCO CIK 0001725255

earnings confidence high sentiment negative materiality 0.70

AdaptHealth Q1 net loss widens to $16M, COO replaced; raises revenue guidance

AdaptHealth Corp.

2026-Q1 EPS reported -$0.12 revenue$819,799,000

Net revenue $819.8M (+5.4% YoY); net loss $16.0M vs $7.2M loss in Q1 2025.
Adjusted EBITDA $121.2M, down 5.3% YoY; free cash flow negative $27.5M.
FY 2026 net revenue guidance raised $10M to $3.45-3.52B; EBITDA and FCF guidance maintained.
COO Toby Scott Barnhart terminated May 4; replaced by Daniel McFadden (Chief Business Systems Officer).
Completed $1.1B refinancing in April, reducing near-term amortization and lowering average debt cost.

item 2.02 item 5.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001628280-26-030120
form_type: 8-K
ticker: AHCO
cik: 0001725255
company_name: AdaptHealth Corp.
filed_at: 2026-05-05T23:59:59+00:00
discovered_at: 2026-05-14T18:02:32.814495+00:00
generated_at: 2026-05-14T23:27:24.688592+00:00
sec_items: ["2.02", "5.02", "9.01"]
event_type: earnings
sentiment: negative
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001628280-26-030120
json_url: https://secwatch.observer/filing/0001628280-26-030120.json
markdown_url: https://secwatch.observer/filing/0001628280-26-030120.md
text_url: https://secwatch.observer/filing/0001628280-26-030120.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1725255/000162828026030120/0001628280-26-030120-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1725255/000162828026030120/ahco-20260505.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel McFadden

Chief Operating Officer

AHCO · AdaptHealth Corp.

Effective: 2026-05-04
Filed: May 5, 2026, 7:59 PM ET

Also on May 4, 2026, the Company appointed Daniel McFadden, the Company’s current Chief Business Systems Officer, as the Company’s Chief Operating Officer.

Departed

Toby Scott Barnhart

Chief Operating Officer

AHCO · AdaptHealth Corp.

Effective: 2026-05-04
Successor: Daniel McFadden
Filed: May 5, 2026, 7:59 PM ET

On May 4, 2026, the Company terminated the employment of Toby Scott Barnhart, the Company’s Chief Operating Officer.

Source-grounded claims

72ecbbdbf7cfebce84ab9b69e370982d53e08bc8

AdaptHealth Corp. reported first quarter ended March 31, 2026 results: revenue $819.8 million, net income $16.0 million. Guidance raised.

the Company's portfolio around its core Sleep and Respiratory Health businesses. First Quarter Results All comparisons are to the quarter ended March 31, 2025. • Net revenue was $819.8 million compared to $777.9 million, an increase of 5.4%. • Organic revenue growth of 9.1%, with growth across each of the Company’s reportable segments. • Net loss attributable to

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

99c9396533

Daniel McFadden was appointed as Chief Operating Officer at AdaptHealth Corp..

Also on May 4, 2026, the Company appointed Daniel McFadden, the Company’s current Chief Business Systems Officer, as the Company’s Chief Operating Officer.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

a06c66ac01

Toby Scott Barnhart was terminated as Chief Operating Officer at AdaptHealth Corp..

On May 4, 2026, the Company terminated the employment of Toby Scott Barnhart, the Company’s Chief Operating Officer.

SEC 8-K Item 5.02 confidence 0.95 SEC evidence

Comparable filings

BRZE

Braze Q1 revenue $211M (+30% YoY), raises guidance, names interim CFO

Braze, Inc. May 27, 2026, 4:09 PM ET earnings Items 2.02, 5.02, 9.01

same fact type: executive_change same SEC item: 2.02, 5.02, 9.01 same event type: earnings similar materiality

This filing

Also on May 4, 2026, the Company appointed Daniel McFadden, the Company’s current Chief Business Systems Officer, as the Company’s Chief Operating Officer.

Comparable filing

On May 25, 2026, the Board of Directors (the “ Board ”) of the Company appointed Pankaj Malik, who currently serves as the Company’s Chief Accounting Officer, as the Company's Interim Chief Financial Officer, effective as of May 29, 2026.

Filing page SEC filing

Agilent Q2 FY26 revenue $1.83B (+10% YoY), non-GAAP EPS $1.49 (+14%), raises FY26 guidance

AGILENT TECHNOLOGIES, INC. May 27, 2026, 4:06 PM ET earnings Items 2.02, 5.02, 9.01

same fact type: executive_change same SEC item: 2.02, 5.02, 9.01 same event type: earnings similar materiality

This filing

Also on May 4, 2026, the Company appointed Daniel McFadden, the Company’s current Chief Business Systems Officer, as the Company’s Chief Operating Officer.

Comparable filing

As previously disclosed, on March 5, 2026, Rodney Gonsalves, informed the Company that he would retire from his position as the Company’s Vice President, Corporate Controller and Principal Accounting Officer, the exact date to be determined at a later time.

Filing page SEC filing

BBWI

BBWI Q1 sales down 3%, adjusted EPS $0.32 beats guidance; CFO Boratto to step down June 12

Bath & Body Works, Inc. May 27, 2026, 7:12 AM ET earnings Items 2.02, 7.01, 5.02, 9.01

same fact type: executive_change same SEC item: 2.02, 5.02, 9.01 same event type: earnings similar materiality

This filing

Also on May 4, 2026, the Company appointed Daniel McFadden, the Company’s current Chief Business Systems Officer, as the Company’s Chief Operating Officer.

Comparable filing

the Board of Directors (the "Board") of the Company approved the appointment of Tom Javitch to serve as the Company’s Interim Chief Financial Officer

Filing page SEC filing

IVF

INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M

INVO Fertility, Inc. June 2, 2026, 8:40 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

the Company's portfolio around its core Sleep and Respiratory Health businesses. First Quarter Results All comparisons are to the quarter ended March 31, 2025. • Net revenue was $819.8 million compared to $777.9 million, an increase of 5.4%. • Organic revenue growth of 9.1%, with growth across each of the Company’s reportable segments. • Net loss attributable to

Comparable filing

and technologies, today announced fiscal year 2025 financial results. FY2025 Financial Highlights (all metrics compared to FY2024 unless otherwise noted) ● Revenue was $6,841,250, an increase of 5% compared to $6,532,000. ● Consolidated clinic revenue increased 4% to $6,721,057, compared to $6,450,431. ● Revenue from all clinics was $8,021,929, including

Filing page SEC filing

POLA

Polar Power Q1 net loss narrows 86% to $178K; gross margin expands to 65.7%

Polar Power, Inc. June 2, 2026, 8:30 AM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

the Company's portfolio around its core Sleep and Respiratory Health businesses. First Quarter Results All comparisons are to the quarter ended March 31, 2025. • Net revenue was $819.8 million compared to $777.9 million, an increase of 5.4%. • Organic revenue growth of 9.1%, with growth across each of the Company’s reportable segments. • Net loss attributable to

Comparable filing

Q1 2026 Q1 2025 Y/Y +/(-) Change Net sales $ 1,728 $ 1,723 — Gross profit $ 1,135 $ 320 255 % Gross margin 65.7 % 18.6 % 47.1 pts Total operating expenses $ 1,111 $ 1,421 22 % Income (loss) from operations $ 24 $ (1,101 ) 102 % Net loss $ (178 ) $ (1,265 ) 86 % Net loss per share $ (0.05 ) $ (0.50 ) 90 %

Filing page SEC filing

CTRN

Citi Trends Q1 sales up 14.4% to $230.9M; adjusted EBITDA doubles to $13.9M

Citi Trends Inc June 2, 2026, 6:58 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

the Company's portfolio around its core Sleep and Respiratory Health businesses. First Quarter Results All comparisons are to the quarter ended March 31, 2025. • Net revenue was $819.8 million compared to $777.9 million, an increase of 5.4%. • Organic revenue growth of 9.1%, with growth across each of the Company’s reportable segments. • Net loss attributable to

Comparable filing

(EXHIBIT 99.1) --- EX-99.1 2 tm2616574d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CITITRENDS ANNOUNCES FIRST QUARTER FISCAL 2026 RESULTS Q1 2026 total sales increased 14.4% to $230.9 million Comparable store sales growth of 13.9%; Two-year stack of 23.8% Q1 2026 Net Income of $7.8 million; Q1 2026 adjusted EBITDA* of $13.9 million, more than double Q1 2025 results

Filing page SEC filing

SIG

Signet Q1 sales $1.6B, SSS +1.8%; raises FY27 adjusted EPS guidance

SIGNET JEWELERS LTD June 2, 2026, 6:54 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

the Company's portfolio around its core Sleep and Respiratory Health businesses. First Quarter Results All comparisons are to the quarter ended March 31, 2025. • Net revenue was $819.8 million compared to $777.9 million, an increase of 5.4%. • Organic revenue growth of 9.1%, with growth across each of the Company’s reportable segments. • Net loss attributable to

Comparable filing

On June 2, 2026, Signet Jewelers Limited (the "Company") issued a press release announcing results for the first quarter ended May 2, 2026.

Filing page SEC filing

Dollar General Q1 EPS $2.00 beats expectations; raises FY2026 EPS guidance

DOLLAR GENERAL CORP June 2, 2026, 6:54 AM ET earnings Items 2.02, 5.07, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

the Company's portfolio around its core Sleep and Respiratory Health businesses. First Quarter Results All comparisons are to the quarter ended March 31, 2025. • Net revenue was $819.8 million compared to $777.9 million, an increase of 5.4%. • Organic revenue growth of 9.1%, with growth across each of the Company’s reportable segments. • Net loss attributable to

Comparable filing

(NYSE: DG) today reported financial results for its first quarter (13 weeks) ended May 1, 2026. First Quarter Fiscal Year 2026 Highlights · Net Sales Increased 3.4% to $10.8 Billion · Same-Store Sales Increased 2.0% · Operating Profit Increased 10.8% to $638.5 Million · Diluted Earnings Per Share (“EPS”) Increased 12.4% to $2.00 · Cash Flow From

Filing page SEC filing

Source: SEC EDGAR

accession 0001628280-26-030120

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.